Log in

PARD PONIARD PHARMACEUT OTC · United States

PONIARD PHARMACEUT (PARD) news

PONIARD PHARMACEUT is a public biotech or pharmaceutical company listed on OTC under the ticker PARD, recorded under United States. The directory classifies it as Biotechnology. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.

Latest PONIARD PHARMACEUT news

We have not published a story on PONIARD PHARMACEUT yet. When there is news, it will appear here.

Questions about PONIARD PHARMACEUT

What is the ticker symbol of PONIARD PHARMACEUT?

PONIARD PHARMACEUT trades under the ticker PARD on OTC.

Where is PONIARD PHARMACEUT listed?

PONIARD PHARMACEUT is listed on OTC.

Which country or territory is PONIARD PHARMACEUT listed under?

Our directory records PONIARD PHARMACEUT under United States.

What does PONIARD PHARMACEUT do?

Our directory classifies PONIARD PHARMACEUT as: Biotechnology. This is a directory classification, not a description of the pipeline.

What is the ISIN of PONIARD PHARMACEUT?

The ISIN recorded for PONIARD PHARMACEUT is US7324494001.

Does aibio.space cover PONIARD PHARMACEUT?

aibio.space lists PONIARD PHARMACEUT among 2,820 public biotech companies and publishes its news here as stories appear.

Which companies are similar to PONIARD PHARMACEUT?

Companies in our directory listed in the same country and business area as PONIARD PHARMACEUT: Range Impact, Galectin Therapeutics, Black Diamond Therapeutics, FibroBiologics, BioCardia, BioMarin Pharmaceutical.

Investor discussion: PONIARD PHARMACEUT

Members talk about PONIARD PHARMACEUT (PARD). Reader posts, not aibio.space reporting, and not investment advice.

Rules
  1. Securities violations are strictly forbidden. No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
  2. Say whether you hold the stock. Every post states long, short or no position.
  3. No paid or sponsored posts. Do not post for anyone who pays or rewards you.
  4. No buy or sell calls and no price targets.
  5. No accusations of crime or fraud against named people unless you link a court filing or a regulator's release that makes them.
  6. No personal details and no spam. No links at all for your first 7 days as a member.

Posts that break the rules may be deleted without notice, and the account restricted or closed. See the terms and the privacy policy.

Stock chart

Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. Open OTC:PARD on TradingView.

Listing details

PONIARD PHARMACEUT is a public biotech or pharmaceutical company listed on OTC under the ticker PARD, recorded under United States. The directory classifies it as Biotechnology. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.

Company
PONIARD PHARMACEUT
Ticker
PARD
Listing
OTC
Country or territory
United States
Business scope
Biotechnology
ISIN
US7324494001
Last quote in directory
2026-10-09
Directory source
Listing page

Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. Tell us about a change. Work at this company? Claim this page.

Published and maintained by aibio.space. Not investment advice. How we work.

Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction

aibio.space

Full desks

Every other company has a starter desk. Search above to open one.

Settings

Appearance
Text size
Motion

Stops the news strip and the share rollers.

Your choices are saved in this browser only.

Free membership

Read aibio.space in full, free

Subscribe with your email address to read every story, company desk and profile in full. It costs nothing. In return, you agree that we may email you, including offers. One click to unsubscribe.

No card, no password. With email, we send one message to confirm your address first. With Google or Facebook we receive only your email address. Not investment advice.